Spectrum Acquiring Allos on Heels of Apaziquone Failure
By Catherine Shaffer
Friday, April 6, 2012
It was a tumultuous day at the market for Spectrum Pharmaceuticals Inc. and Allos Therapeutics Inc., as investors responded simultaneously to news of the two companies' merger and the failure of Spectrum's cancer drug apaziquone in two Phase III trials.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.